Literature DB >> 479373

Erythrocyte adenosine deaminase deficiency without immunodeficiency. Evidence for an unstable mutant enzyme.

R Hirschhorn, V Roegner, T Jenkins, C Seaman, S Piomelli, W Borkowsky.   

Abstract

Inherited deficiency of the purine salvage enzyme adenosine deaminase (ADA) gives rise to a syndrome of severe combined immunodeficiency (SCID). We have studied a 2.5-yr-old immunologically normal child who had been found to lack ADA in his erythrocytes during New York State screening of normal newborns. His erythrocytes were not detectably less deficient in ADA than erythrocytes of ADA(-)-SCID patients. In contrast, his lymphocytes and cultured long-term lymphoid cells contained appreciably greater ADA activity than those from patients with ADA(-)-SCID. This residual ADA activity had a normal molecular weight and K(m) but was markedly unstable at 56 degrees C. His residual erythrocytes-ADA activity also appeared to have diminished stability in vivo. ADA activity in lymphoid line cells of a previously reported erythrocyte-ADA-deficient!Kung tribesman was found to contain 50% of normal activity and to exhibit diminished stability at 56 degrees C. ATP content of erythrocytes from both partially ADA-deficient individuals was detectably greater than normal (12.3 and 6.1 vs. normal of 2.6 nmol/ml packed erythrocytes). However, the dATP content was insignificant compared to that found in erythrocytes of ADA(-)-SCID patients (400-1,000 nmol/ml packed erythrocytes). The New York patient, in contrast to normals, excreted detectable amounts of deoxyadenosine, but this was <2% of deoxyadenosine excreted by ADA(-)-SCID patients. Thus, the residual enzyme in cells other than erythrocytes appears to be sufficient to almost totally prevent accumulation of toxic metabolites.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 479373      PMCID: PMC372225          DOI: 10.1172/JCI109552

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s).

Authors:  D A Carson; J Kaye; J E Seegmiller
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

2.  Characterization of the residual adenosine deaminating activity in the spleen of a patient with combined immunodeficiency disease and adenosine deaminase deficiency.

Authors:  W P Schrader; B Pollara; H J Meuwissen
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

3.  The effect of adenosine on mitogenesis of ADA-deficient lymphocytes.

Authors:  J Uberti; J J Lightbody; J W Wolf; J A Anderson; R H Reid; R M Johnson
Journal:  Clin Immunol Immunopathol       Date:  1978-08

4.  Identification and quantitation of adenine deoxynucleotides in erythrocytes of a patient with adenosine deaminase deficiency and severe combined immunodeficiency.

Authors:  M S Coleman; J Donofrio; J J Hutton; L Hahn; A Daoud; B Lampkin; J Dyminski
Journal:  J Biol Chem       Date:  1978-03-10       Impact factor: 5.157

5.  Adenosine deaminase. Alterations in activity and isozymes during growth of normal and genetically deficient fibroblasts.

Authors:  R Hirschhorn; N G Beratis; F Martiniuk
Journal:  Exp Cell Res       Date:  1978-11       Impact factor: 3.905

6.  In vivo and in vitro effects of thymosin and adenosine deaminase on adenosine-deaminase-deficient lymphocytes.

Authors:  A Rubinstein; R Hirschhorn; M Sicklick; R A Murphy
Journal:  N Engl J Med       Date:  1979-02-22       Impact factor: 91.245

7.  Human adenosine deaminase binding protein. Assay, purification, and properties.

Authors:  P E Daddona; W N Kelley
Journal:  J Biol Chem       Date:  1978-07-10       Impact factor: 5.157

8.  Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency.

Authors:  A Cohen; R Hirschhorn; S D Horowitz; A Rubinstein; S H Polmar; R Hong; D W Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

9.  Red cell adenosine deaminase (ADA) polymorphism in Southern Africa, with special reference to ADA deficiency among the !Kung.

Authors:  T Jenkins; A B Lane; G T Nurse; D A Hopkinson
Journal:  Ann Hum Genet       Date:  1979-05       Impact factor: 1.670

10.  Use of the integrated steady state rate equation to investigate product inhibition of human red cell adenosine deaminase and its relevance to immune dysfunction.

Authors:  W R Osborne; S H Chen; C R Scott
Journal:  J Biol Chem       Date:  1978-01-25       Impact factor: 5.157

View more
  24 in total

1.  Homozygosity for a newly identified missense mutation in a patient with very severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID).

Authors:  R Hirschhorn; V Chakravarti; J Puck; S D Douglas
Journal:  Am J Hum Genet       Date:  1991-10       Impact factor: 11.025

Review 2.  The biochemical basis of immunodeficiency disease.

Authors:  K O Raivio
Journal:  Eur J Pediatr       Date:  1980-10       Impact factor: 3.183

3.  Sequence of human adenosine deaminase cDNA including the coding region and a small intron.

Authors:  D A Wiginton; G S Adrian; J J Hutton
Journal:  Nucleic Acids Res       Date:  1984-03-12       Impact factor: 16.971

4.  Adenosine deaminase deficiency with normal immune function. An acidic enzyme mutation.

Authors:  P E Daddona; B S Mitchell; H J Meuwissen; B L Davidson; J M Wilson; C A Koller
Journal:  J Clin Invest       Date:  1983-08       Impact factor: 14.808

5.  Adenosine deaminase and purine nucleoside phosphorylase deficiencies: evaluation of therapeutic interventions in eight patients.

Authors:  M L Markert; M S Hershfield; R I Schiff; R H Buckley
Journal:  J Clin Immunol       Date:  1987-09       Impact factor: 8.317

6.  Partial adenosine deaminase deficiency: another family from southern Africa.

Authors:  S L Hart; A B Lane; T Jenkins
Journal:  Hum Genet       Date:  1986-11       Impact factor: 4.132

7.  Biochemical and functional abnormalities in lymphocytes from an adenosine deaminase-deficient patient during enzyme replacement therapy.

Authors:  J J Hutton; D A Wiginton; M S Coleman; S A Fuller; S Limouze; B C Lampkin
Journal:  J Clin Invest       Date:  1981-08       Impact factor: 14.808

8.  Combined familial adenosine deaminase and purine nucleoside phosphorylase deficiencies.

Authors:  A Shanon; S Levin; F Holtzman; F Brock-Sinai; A Abu-Said
Journal:  Arch Dis Child       Date:  1988-08       Impact factor: 3.791

9.  Genetic heterogeneity in adenosine deaminase (ADA) deficiency: five different mutations in five new patients with partial ADA deficiency.

Authors:  R Hirschhorn; A Ellenbogen
Journal:  Am J Hum Genet       Date:  1986-01       Impact factor: 11.025

10.  Characterization of normal and mutant adenosine deaminase messenger RNAs by translation and hybridization to a cDNA probe.

Authors:  G S Adrian; D A Wiginton; J J Hutton
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.